ArticleAnnals of dermatology2023
Guidelines for the Management of Patients with Alopecia Areata in Korea: Part I Topical and Device-based Treatment.
Article in Annals of dermatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
- The Role of Inflammasome in the Pathogenesis of Alopecia Areata: NLRP3 and Its Cascade Contribute to the Onset and Early Stage of Alopecia Areata.Annals of dermatology · 2026Article
- The Role of T-Helper 17 Cells and Regulatory T Cells in Acute Diffuse and Total Alopecia: The Increased Function of Regulatory T Cells May Explain the Favorable Prognosis.The Journal of dermatology · 2025Article
- Survey on Alopecia Areata Patients' Reported Factors that Determine Severity of Alopecia Areata: A Nationwide Multicenter Study.Annals of dermatology · 2024Article
- Korean Consensus Criteria for the Severity Classification of Alopecia Areata.Annals of dermatology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 11 institutions in 1 country.
Funding
Abstract
backgroundAlopecia areata (AA) is a chronic disease with an unpredictable disease course and severe psychological impact.
objectiveTo provide evidence- and consensus-based insights regarding the treatment of patients with AA in Korea.
methodsWe searched for relevant studies on the topical and device-based treatment of AA in the literature from inception until May 2021. Evidence-based recommendations were also prepared. The evidence for each statement was graded and classified according to the strength of the recommendations. Hair experts from the Korean Hair Research Society (KHRS) voted on the statements, and an agreement of 75% or greater was considered as consensus.
resultsCurrently, there remains a scarcity of topical treatments, which is supported by robust evidence from a number of high-quality randomized controlled trials. Current evidence supports the efficacy of topical corticosteroids, corticosteroid intralesional injection, and contact immunotherapy in AA patients. Topical corticosteroids and contact immunotherapy are recommended for pediatric AA. A consensus was achieved in 6 out of 14 (42.8%), and 1 out of 5 (20.0%) statements pertaining to topical and device-based treatments in AA, respectively. The expert consensus was from a single country, and the study may not cover all the treatments used.
conclusionThe present study provides up-to-date, evidence-based treatment guidelines for AA based on the consensus reached among experts after considering regional healthcare circumstances, adding diversity to the previous guidelines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.